The financial regulations require hedge funds and wealthy investors that exceeded the $100 million holdings threshold to file a report that shows their positions at the end of every quarter. Even though it isn’t the intention, these filings to a certain extent level the playing field for ordinary investors. The latest round of 13F filings […]
Elanco Animal Health said Wednesday it would buy Kindred Biosciences for roughly $440 million, sending KIN stock soaring.
Elanco Animal Health said it struck a $440 million deal to acquire Kindred Biosciences, a move that will bolster its drug pipeline, particularly the fast-growing pet dermatology segment.